受强制性开放获取政策约束的文章 - Nola Hylton了解详情
无法在其他位置公开访问的文章：2 篇
Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis
SG Elias, A Adams, DJ Wisner, LJ Esserman, LJ van't Veer, WPTM Mali, ...
Cancer epidemiology, biomarkers & prevention 23 (8), 1464-1483, 2014
强制性开放获取政策： Dutch Cancer Society
Diffusion-weighted MRI in multicenter trials of breast cancer
SC Partridge, DC Newitt, TL Chenevert, MA Rosen, NM Hylton, ...
Radiology 291 (2), 546-546, 2019
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：124 篇
I‐SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
AD Barker, CC Sigman, GJ Kelloff, NM Hylton, DA Berry, LJ Esserman
Clinical Pharmacology & Therapeutics 86 (1), 97-100, 2009
强制性开放获取政策： US National Institutes of Health
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively …
R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ...
JAMA oncology 6 (5), 676-684, 2020
强制性开放获取政策： US National Institutes of Health
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
强制性开放获取政策： US National Institutes of Health
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL
NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ...
Radiology 263 (3), 663-672, 2012
强制性开放获取政策： US National Institutes of Health
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ...
Journal of Clinical Oncology 30 (26), 3242-3249, 2012
强制性开放获取政策： US National Institutes of Health
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
强制性开放获取政策： US National Institutes of Health
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132, 1049-1062, 2012
强制性开放获取政策： US National Institutes of Health
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ...
The Lancet Oncology 23 (1), 149-160, 2022
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, National Institute for …
Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
NM Hylton, CA Gatsonis, MA Rosen, CD Lehman, DC Newitt, ...
Radiology 279 (1), 44-55, 2016
强制性开放获取政策： US National Institutes of Health
Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial
SC Partridge, Z Zhang, DC Newitt, JE Gibbs, TL Chenevert, MA Rosen, ...
Radiology 289 (3), 618-627, 2018
强制性开放获取政策： US National Institutes of Health
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
ER Garwood, AS Kumar, FL Baehner, DH Moore, A Au, N Hylton, ...
Breast cancer research and treatment 119, 137-144, 2010
强制性开放获取政策： US National Institutes of Health
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer …
JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ...
Cancer 119 (10), 1776-1783, 2013
强制性开放获取政策： US National Institutes of Health
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ...
Cancer cell 39 (7), 989-998. e5, 2021
强制性开放获取政策： US National Institutes of Health
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
DM Wolf, C Yau, J Wulfkuhle, L Brown-Swigart, RI Gallagher, PRE Lee, ...
Cancer Cell 40 (6), 609-623. e6, 2022
强制性开放获取政策： US National Institutes of Health, State of Califonia
Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer …
D Yee, AM DeMichele, C Yau, C Isaacs, WF Symmans, KS Albain, ...
JAMA oncology 6 (9), 1355-1362, 2020
强制性开放获取政策： US National Institutes of Health
Agreement of mammographic measures of volumetric breast density to MRI
J Wang, A Azziz, B Fan, S Malkov, C Klifa, D Newitt, S Yitta, N Hylton, ...
PloS one 8 (12), e81653, 2013
强制性开放获取政策： US National Institutes of Health
Predicting responses to neoadjuvant chemotherapy in breast cancer: ACRIN 6691 trial of diffuse optical spectroscopic imaging
BJ Tromberg, Z Zhang, A Leproux, TD O'Sullivan, AE Cerussi, ...
Cancer research 76 (20), 5933-5944, 2016
强制性开放获取政策： US National Institutes of Health
Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort
C Klifa, J Carballido-Gamio, L Wilmes, A Laprie, J Shepherd, J Gibbs, ...
Magnetic resonance imaging 28 (1), 8-15, 2010
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定